CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Nivolumab +2 moredrug
Likely dose
Nivolumab 240mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03267498
NCT03267498Phase 2Completed
CompareCT.gov

Nivolumab in Combination With Chemoradiation for Patients With Stage II-IVB Nasopharyngeal Carcinoma, A Phase II Study With Correlative Biomarkers

Sue Yom·interventional·Posted Aug 30, 2017·Updated Jan 12, 2026

In Brief

A Phase 2 clinical trial evaluating Nivolumab, Cisplatin, and 1 other intervention for Nasopharyngeal Carcinoma. Completed, enrolled 40 participants across 2 sites in 2 countries.

Detailed Summary

This phase II trial studies how well nivolumab and chemoradiotherapy works in treating patients with stage II-IVB nasopharyngeal cancer. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells. Chemoradiotherapy is the combination of chemotherapy and radiation therapy and may prevent the cancer from spreading when combined with nivolumab. Giving nivolumab and chemoradiotherapy may work better in treating patients with stage II-IVB nasopharyngeal cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesSingapore, United States
CollaboratorsNational University of Singapore, Bristol-Myers Squibb

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 30, 2017
Enrollment StartFeb 14, 2018
Primary CompletionOct 31, 2024
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 8.8 years ago

Interventions

Nivolumabdrug

Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.

Cisplatindrug

Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.

Radiation Therapyradiation

2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday